XDH-Targeting RNA Oligonucleotide Composition for Uric Acid Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies are inadequate for effectively targeting the XDH gene to prevent diseases associated with chronic hyperuricemia, such as gout, due to inadequate renal clearance or excessive uric acid production.
Innovation Solution
The use of specific RNA oligonucleotides, including RNAi oligonucleotides, designed to target and inhibit XDH expression by binding to XDH mRNA sequences, thereby reducing XDH activity in the liver.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current strategies are used to target XDH gene, then treatment approaches are limited, but effectiveness in preventing gout and hyperuricemia is inadequate
Solution Approach 1:
The patent divides the treatment approach into two distinct RNA oligonucleotide components (first and second oligonucleotides) that work together to inhibit XDH expression. This segmentation allows for optimized individual functions while achieving superior overall efficacy compared to single-oligonucleotide approaches, directly addressing the inadequacy of current treatment strategies.
Solution Approach 2:
The invention uses composite RNA oligonucleotide structures with modified nucleotides and specific sequence compositions (SEQ ID NO: 21-24) to create a more effective therapeutic agent. This composite approach combines multiple functional elements within the oligonucleotides to enhance stability, targeting efficiency, and gene silencing capability, thereby improving treatment reliability.
2Reliability
If RNA oligonucleotides are designed to bind XDH mRNA sequences, then XDH expression is reduced, but the complexity of the therapeutic composition increases
Solution Approach 1:
The patent combines two RNA oligonucleotides into a single therapeutic composition that functions as an integrated unit. The first and second oligonucleotides are designed to work synergistically to inhibit XDH expression, merging multiple functional capabilities into a coordinated therapeutic system that achieves reliable gene silencing while maintaining manageable composition complexity.
Solution Approach 2:
The invention optimizes specific parameters of the RNA oligonucleotides including sequence composition (SEQ ID NO: 21-24), modified nucleotide incorporation, and structural features to enhance XDH binding affinity and silencing efficiency. By carefully adjusting these parameters, the patent achieves effective XDH expression inhibition while controlling the complexity of the therapeutic composition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RNA oligonucleotides effectively reduce XDH expression, leading to decreased serum uric acid levels and providing a therapeutic approach for conditions like gout and hyperuricemia.
Implementation Method 1
designed to target and inhibit XDH expression by binding to XDH mRNA sequences
Data Source
AI summary
Oligonucleotides are provided herein that inhibit XDH expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with aberrant XDH expression.